bioAffinity Technologies, Inc. (BIAF)

bioAffinity Technologies' stock price experienced a significant decline of 95.81% between January 6, 2025, and January 2, 2026. In November 2025, the stock dipped sharply following the company's third-quarter 2025 earnings report, which reflected lower sales but a wider net loss, primarily due to a non-cash expense from warrant revaluations. Despite the overall revenue decline, CyPath® Lung testing revenue rose by 122% year-over-year in Q3 2025, driven by increased case volumes and physician adoption. Similarly, in August 2025, the stock was down following Q2 earnings, despite reported growth in CyPath® Lung. A 1-30 reverse stock split was enacted before market open on September 19, 2025. Positive news included the company's laboratory maintaining College of American Pathologists (CAP) Accreditation in January 2026, and the CyPath® Lung test being highlighted at the American Cancer Society National Lung Cancer Roundtable in December 2025. In November 2025, bioAffinity Technologies also reported accelerating month-over-month growth in CyPath® Lung test volume.

There is no indication of significant demand seasonality for bioAffinity Technologies' products and services. The company has reported consistent month-over-month and quarter-over-quarter growth in the sales volume of its CyPath® Lung test, with October 2025 test volume rising 111% over the 2025 monthly average, suggesting a growing adoption and demand for its diagnostic test rather than seasonal fluctuations.

bioAffinity Technologies, Inc. is a biotechnology company focused on early-stage cancer diagnosis and targeted treatments, operating in the Health Care sector, specifically in the Biotechnology industry. Its primary product, CyPath® Lung, is a non-invasive diagnostic test for early-stage lung cancer detection, utilizing flow cytometry and machine learning to analyze sputum samples. The test aims to improve diagnostic accuracy, survival rates, and reduce unnecessary procedures and medical costs. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) through Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.

bioAffinity Technologies, Inc. is headquartered in San Antonio, Texas, and initially focused its CyPath® Lung product launch within Texas. The company has experienced growing usage of CyPath® Lung across Veterans Administration (VA) medical centers and in new regional markets within the United States, indicating an expanding domestic operational reach.

bioAffinity Technologies has seen positive developments impacting its brand reputation, including the company's laboratory maintaining its College of American Pathologists (CAP) Accreditation in January 2026. Additionally, in December 2025, the non-invasive CyPath® Lung test was highlighted at the American Cancer Society National Lung Cancer Roundtable. The consistent month-over-month and quarter-over-quarter growth in CyPath® Lung test volume, with October 2025 volume increasing 111% over the year-to-date monthly average, further underscores increasing physician recognition and trust in the clinical value of the test.

bioAffinity Technologies, Inc. has a notable institutional ownership presence, with 14 institutional owners and shareholders holding a total of 276,856 shares as of late 2025. Major institutional owners include Sabby Management, Llc, Scientech Research LLC, Vanguard Group Inc, Tower Research Capital LLC (TRC), Allworth Financial LP, Bank Of America Corp /de/, IFP Advisors, Inc, UBS Group AG, Citigroup Inc, and Larson Financial Group LLC. Sabby Management, LLC is among the largest shareholders, holding 242,757 shares as of September 30, 2025. Institutional investors collectively own 1.64% to 2.81% of bioAffinity Technologies' stock. Insider sentiment for BIAF is positive, with 15 different insiders buying shares over the last year, totaling approximately $3.60 million in purchases.